Sign up to save your podcasts
Or
Share Matthew D. Galsky, MD, Neal D. Shore, MD, FACS - The New Immuno-Oncology Era in Early-Stage Bladder Cancer: Readying the Modern Urology Practice
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Matthew D. Galsky, MD, Neal D. Shore, MD, FACS - The New Immuno-Oncology Era in Early-Stage Bladder Cancer: Readying the Modern Urology Practice
Go online to PeerView.com/FPT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you fully prepared as we move further into the immune checkpoint inhibitor (ICI) era in early-stage bladder cancer? Already well established in metastatic urothelial carcinoma, the role of ICIs has now been validated and resulted in regulatory approvals in both non–muscle-invasive bladder cancer (NMIBC) and high-risk muscle-invasive bladder cancer (MIBC). In this interdisciplinary discussion, two bladder cancer experts provide practical guidance on the use of ICIs in the treatment of patients with early-stage bladder cancer, including as part of bladder-sparing and perioperative approaches. Hear about accumulating evidence on these agents and learn guideline-based strategies for incorporating immunotherapy into personalized treatment plans and collaborating with other members of the cancer care team to manage immune-related adverse events and improve outcomes for your patients. Upon completion of this activity, participants should be better able to: Appraise accumulating evidence on immunotherapy strategies for bladder cancer management in early-stage disease; Incorporate approved and emerging immunotherapeutic approaches in personalized treatment plans for patients with early-stage bladder cancer, considering the available evidence, guidelines, and principles of multidisciplinary and patient-centered care; and Design and collaborate on evidence- and team-based management protocols to address the unique suite of adverse events associated with immunotherapeutic treatment options in bladder cancer.
View all episodes
By PVI, PeerView Institute for Medical Education
4.3
99 ratings
Go online to PeerView.com/FPT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you fully prepared as we move further into the immune checkpoint inhibitor (ICI) era in early-stage bladder cancer? Already well established in metastatic urothelial carcinoma, the role of ICIs has now been validated and resulted in regulatory approvals in both non–muscle-invasive bladder cancer (NMIBC) and high-risk muscle-invasive bladder cancer (MIBC). In this interdisciplinary discussion, two bladder cancer experts provide practical guidance on the use of ICIs in the treatment of patients with early-stage bladder cancer, including as part of bladder-sparing and perioperative approaches. Hear about accumulating evidence on these agents and learn guideline-based strategies for incorporating immunotherapy into personalized treatment plans and collaborating with other members of the cancer care team to manage immune-related adverse events and improve outcomes for your patients. Upon completion of this activity, participants should be better able to: Appraise accumulating evidence on immunotherapy strategies for bladder cancer management in early-stage disease; Incorporate approved and emerging immunotherapeutic approaches in personalized treatment plans for patients with early-stage bladder cancer, considering the available evidence, guidelines, and principles of multidisciplinary and patient-centered care; and Design and collaborate on evidence- and team-based management protocols to address the unique suite of adverse events associated with immunotherapeutic treatment options in bladder cancer.
More shows like PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
View all
PeerView Endocrinology & Diabetes CME/CNE/CPE Audio Podcast
5 Listeners
Lung Cancer Update
32 Listeners
PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast
3 Listeners
PeerView Gastroenterology CME/CNE/CPE Audio Podcast
3 Listeners
PeerView Neuroscience & Psychiatry CME/CNE/CPE Audio Podcast
11 Listeners
PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast
5 Listeners
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
27 Listeners
PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
10 Listeners
PeerView Gastroenterology CME/CNE/CPE Video Podcast
3 Listeners
PeerView Internal Medicine CME/CNE/CPE Video Podcast
2 Listeners
PeerView Neuroscience & Psychiatry CME/CNE/CPE Video Podcast
4 Listeners
PeerView Endocrinology & Diabetes CME/CNE/CPE Video Podcast
3 Listeners
PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast
3 Listeners
PeerView Infectious Diseases CME/CNE/CPE Audio Podcast
5 Listeners
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast
5 Listeners
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast
2 Listeners
Hematologic Oncology Update
72 Listeners
PeerView Infectious Diseases CME/CNE/CPE Video Podcast
0 Listeners
PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
9 Listeners
NEJM This Week
325 Listeners
Journal of Clinical Oncology (JCO) Podcast
38 Listeners
PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast
2 Listeners
Research To Practice | Oncology Videos
113 Listeners
PeerView Clinical Pharmacology CME/CNE/CPE Video
2 Listeners
Exchanges
991 Listeners
ASCO Daily News
58 Listeners
The Curbsiders Internal Medicine Podcast
3,332 Listeners
ASCO Guidelines
43 Listeners
OncLive® On Air
21 Listeners
The Clinical Problem Solvers
515 Listeners
Oncology Today with Dr Neil Love
56 Listeners
Two Onc Docs
169 Listeners
Oncology Brothers: Practice-Changing Cancer Discussions
39 Listeners